Article
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
Nature - 1 Oct 2020
Corbett Kizzmekia S, Edwards Darin K, Leist Sarah R, Abiona Olubukola M, Boyoglu-Barnum Seyhan, Gillespie Rebecca A, Himansu Sunny, Schäfer Alexandra, Ziwawo Cynthia T, DiPiazza Anthony T, Dinnon Kenneth H, Elbashir Sayda M, Shaw Christine A, Woods Angela, Fritch Ethan J, Martinez David R, Bock Kevin W, Minai Mahnaz, Nagata Bianca M, Hutchinson Geoffrey B, Wu Kai, Henry Carole, Bahl Kapil, Garcia-Dominguez Dario, Ma LingZhi, Renzi Isabella, Kong Wing-Pui, Schmidt Stephen D, Wang Lingshu, Zhang Yi, Phung Emily, Chang Lauren A, Loomis Rebecca J, Altaras Nedim Emil, Narayanan Elisabeth, Metkar Mihir, Presnyak Vlad, Liu Cuiping, Louder Mark K, Shi Wei, Leung Kwanyee, Yang Eun Sung, West Ande, Gully Kendra L, Stevens Laura J, Wang Nianshuang, Wrapp Daniel, Doria-Rose Nicole A, Stewart-Jones Guillaume, Bennett Hamilton, Alvarado Gabriela S, Nason Martha C, Ruckwardt Tracy J, McLellan Jason S, Denison Mark R, Chappell James D, Moore Ian N, Morabito Kaitlyn M, Mascola John R, Baric Ralph S, Carfi Andrea, Graham Barney S
Abstract excerpt
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusion state, improving their expression and increasing immunogenicity1. This principle has been applied to design mRNA-1273, an mRNA vaccine that...
Read the complete abstract on PubMed